Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)
The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled study ISAR-REACT 5. Prasugrel should be consi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2019-11-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839576723509739520 |
|---|---|
| author | S. N. Tereshchenko M. G. Glezer S. A. Abugov O. V. Averkov S. I. Antipov A. S. Galyavich M. Yu. Gilyarov D. V. Duplyakov A. A. Efremushkina D. A. Zateyshchikov V. V. Ivanenko E. D. Kosmacheva O. V. Krestyaninov Yu. M. Lopatin E. P. Panchenko V. V. Ryabov E. V. Samokhvalov I. I. Staroverov S. A. Ustyugov A. V. Khripun S. V. Shalaev R. M. Shakhnovich I. S. Yavelov A. N. Yakovlev S. S. Yakushin |
| author_facet | S. N. Tereshchenko M. G. Glezer S. A. Abugov O. V. Averkov S. I. Antipov A. S. Galyavich M. Yu. Gilyarov D. V. Duplyakov A. A. Efremushkina D. A. Zateyshchikov V. V. Ivanenko E. D. Kosmacheva O. V. Krestyaninov Yu. M. Lopatin E. P. Panchenko V. V. Ryabov E. V. Samokhvalov I. I. Staroverov S. A. Ustyugov A. V. Khripun S. V. Shalaev R. M. Shakhnovich I. S. Yavelov A. N. Yakovlev S. S. Yakushin |
| author_sort | S. N. Tereshchenko |
| collection | DOAJ |
| description | The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled study ISAR-REACT 5. Prasugrel should be considered the preferred P2Y12 receptor blocker in the planned primary percutaneous coronary intervention and early invasive management of patients with ST segment elevation ACS. Herewith, prasugrel intake in patients with non-ST segment elevation ACS is preferable after coronary angiography and decision for coronary stenting. |
| format | Article |
| id | doaj-art-b0924fb65646460c953c5a5df9f6739a |
| institution | Matheson Library |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2019-11-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-b0924fb65646460c953c5a5df9f6739a2025-08-04T13:00:21Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202019-11-01011929710.15829/1560-4071-2019-11-92-972809Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)S. N. Tereshchenko0M. G. Glezer1S. A. Abugov2O. V. Averkov3S. I. Antipov4A. S. Galyavich5M. Yu. Gilyarov6D. V. Duplyakov7A. A. Efremushkina8D. A. Zateyshchikov9V. V. Ivanenko10E. D. KosmachevaO. V. Krestyaninov11Yu. M. Lopatin12E. P. Panchenko13V. V. Ryabov14E. V. Samokhvalov15I. I. Staroverov16S. A. Ustyugov17A. V. Khripun18S. V. Shalaev19R. M. Shakhnovich20I. S. Yavelov21A. N. Yakovlev22S. S. Yakushin23НМИЦ кардиологии Минздрава России; РМАНПО Минздрава РоссииПервый МГМУ им. И.М. Сеченова Минздрава РоссииРНЦХ им. академика Б.В. Петровского; Российская Медицинская академия последипломного образованияГКБ № 15 им. О.М. ФилатоваТомская областная клиническая больницаМежрегиональный клинико-диагностический центр; КГМУГКБ № 1 им. Н.И. ПироговаСамарский областной клинический кардиологический диспансерАлтайский государственный медицинский университетЦентральная государственная медицинская академия УД Президента РФ; Городская клиническая больница № 51Волгоградский областной клинический кардиологический центрЦентр интервенционной кардиологииВолгоградский государственный медицинский университет; Волгоградский областной клинический кардиологический центрНМИЦ кардиологии Минздрава РоссииНИИ кардиологии Томского НИМЦККБ № 1 КрасноярскаНМИЦ кардиологии Минздрава РоссииККБ № 1 КрасноярскаРостовская областная клиническая больницаТюменский государственный медицинский университетНМИЦ кардиологии Минздрава РоссииНМИЦ профилактической медицины Минздрава РоссииНМИЦ им. В. А. Алмазова Минздрава РоссииРязанский государственный медицинский университет им. академика И.П. ПавловаThe conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled study ISAR-REACT 5. Prasugrel should be considered the preferred P2Y12 receptor blocker in the planned primary percutaneous coronary intervention and early invasive management of patients with ST segment elevation ACS. Herewith, prasugrel intake in patients with non-ST segment elevation ACS is preferable after coronary angiography and decision for coronary stenting.https://russjcardiol.elpub.ru/jour/article/view/3640acute coronary syndromeprasugrelp2y12 receptor blocker |
| spellingShingle | S. N. Tereshchenko M. G. Glezer S. A. Abugov O. V. Averkov S. I. Antipov A. S. Galyavich M. Yu. Gilyarov D. V. Duplyakov A. A. Efremushkina D. A. Zateyshchikov V. V. Ivanenko E. D. Kosmacheva O. V. Krestyaninov Yu. M. Lopatin E. P. Panchenko V. V. Ryabov E. V. Samokhvalov I. I. Staroverov S. A. Ustyugov A. V. Khripun S. V. Shalaev R. M. Shakhnovich I. S. Yavelov A. N. Yakovlev S. S. Yakushin Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5) Российский кардиологический журнал acute coronary syndrome prasugrel p2y12 receptor blocker |
| title | Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5) |
| title_full | Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5) |
| title_fullStr | Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5) |
| title_full_unstemmed | Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5) |
| title_short | Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5) |
| title_sort | place of prasugrel p2y12 receptor antagonist in an early invasive treatment of patients with acute coronary syndrome according to the results of multicenter randomized controlled trial isar react 5 |
| topic | acute coronary syndrome prasugrel p2y12 receptor blocker |
| url | https://russjcardiol.elpub.ru/jour/article/view/3640 |
| work_keys_str_mv | AT sntereshchenko placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT mgglezer placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT saabugov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT ovaverkov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT siantipov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT asgalyavich placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT myugilyarov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT dvduplyakov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT aaefremushkina placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT dazateyshchikov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT vvivanenko placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT edkosmacheva placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT ovkrestyaninov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT yumlopatin placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT eppanchenko placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT vvryabov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT evsamokhvalov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT iistaroverov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT saustyugov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT avkhripun placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT svshalaev placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT rmshakhnovich placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT isyavelov placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT anyakovlev placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 AT ssyakushin placeofprasugrelp2y12receptorantagonistinanearlyinvasivetreatmentofpatientswithacutecoronarysyndromeaccordingtotheresultsofmulticenterrandomizedcontrolledtrialisarreact5 |